**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 80242

**Manuscript Type:** MINIREVIEWS

**Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion**

Li J *et al*. Adjuvant therapy for HCC with MVI

Jiang Li, Fan Yang, Jian Li, Zhi-Yong Huang, Qi Cheng, Er-Lei Zhang

**Jiang Li, Jian Li, Zhi-Yong Huang, Qi Cheng, Er-Lei Zhang,** Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China

**Jiang Li,** Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Shihezi University, Shihezi 832000, Xinjiang Uygur Autonomous Regions, China

**Fan Yang,** Department of General Surgery, Affiliated Hospital of Hubei Minzu University, Enshi 445000, Hubei Province, China

**Author contributions:** Zhang EL and Cheng Q contributed to the study design, Zhang EL and Cheng Q as the co-corresponding author of this manuscript; Li J, Yang F, and Li J contributed to the collection of the data; Li J and Huang ZY contributed to the analysis and interpretation of the data and the writing of the article; Zhang EL contributed to the financial support; Cheng Q and Zhang EL contributed to the revision of the article and statistical analysis; and all authors read and approved the final version of the article.

**Supported by** the National Natural Science Foundation of China, No. 81902839.

**Corresponding author: Er-Lei Zhang, MD, PhD, Doctor,** Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Dadao, Wuhan 430030, Hubei Province, China. baiyu19861104@163.com

**Received:** September 21, 2022

**Revised:** October 29, 2022

**Accepted:** December 21, 2022

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is one of the most lethal tumors in the world. Liver resection (LR) and liver transplantation (LT) are widely considered as radical treatments for early HCC. However, the recurrence rates after curative treatment are still high and overall survival is unsatisfactory. Microvascular invasion (MVI) is considered to be one of the important prognostic factors affecting postoperative recurrence and long-term survival. Unfortunately, whether HCC patients with MVI should receive postoperative adjuvant therapy remains unknown. In this review, we summarize the therapeutic effects of transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine protein kinase inhibitor-based targeted therapy, and immune checkpoint inhibitors in patients with MVI after LR or LT, aiming to provide a reference for the best adjuvant treatment strategy for HCC patients with MVI after LT or LR.

**Key Words:** Microvascular invasion; Hepatocellular carcinoma; Liver resection; Liver transplantation; Postoperative; Adjuvant treatment

Li J, Yang F, Li J, Huang ZY, Cheng Q, Zhang EL. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. *World J Gastrointest Surg* 2022; In press

**Core Tip:** Microvascular invasion (MVI) is considered to be one of the important prognostic factors affecting postoperative recurrence and long-term survival. Unfortunately, whether hepatocellular carcinoma (HCC) patients with MVI should receive postoperative adjuvant therapy remains unknown. In this review, we summarize the therapeutic effects of transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine protein kinase inhibitor-based targeted therapy, and immune checkpoint inhibitors in patients with MVI after liver resection (LR) or liver transplantation (LT), aiming to provide a reference for the best adjuvant treatment strategy for HCC patients with MVI after LT or LR.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the seventh most common cancer and the second leading cause of cancer-related deaths in the world, with unsatisfactory long-term outcomes[1]. Nowadays, hepatectomy liver resection (LR) and liver transplantation (LT) are still the most efficient strategies for HCC with relatively preserved liver function[2]. Unfortunately, the surgical resection rate of HCC is still low in clinical practice due to untimely diagnosis and delayed treatment in most HCC patients. Even with radical surgery, the 5-year recurrence rate is still 70%-80%[3]. Accordingly, decreasing the recurrence rate after surgical resection is of utmost importance to improve the clinical outcomes for early-stage HCC patients.

Various risk factors are associated with the recurrence of HCC. Malignant biological characteristics of the tumor and the condition of the underlying liver disease, such as hepatitis and liver cirrhosis, were found to be more significant prognostic factors than tumor size and warrant closer attention in clinical practice[4]. Among malignant biological characteristics of HCC, microvascular invasion (MVI) is considered a risk factor for intrahepatic microscopic metastatic disease and one of the crucial factors for early HCC recurrence after LR or LT. As a consequence, In the 8th edition of the American Joint Committee on Cancer staging system, it was further included as an important prognostic factor, where it is considered an independent risk factor for poor clinical outcomes[5]. Currently, MVI is usually defined as tumor cells invading into the portal vein, hepatic vein, or a large capsular vessel of the surrounding tumor tissues, partially or totally lined by endothelial cells visible only by microscopical examination of specimens obtained from surgical excision, which is acknowledged as a histological feature[6]. MVI plays a crucial role in the selection of surgical modalities and also a vital indicator of early tumor recurrence in HCC patients[7]. Due to differences of MVI status, the surgical outcomes are likely inconsistent among different treatment groups. The presence of MVI in HCC is strongly correlated with the recurrence rates after surgical resection and should be classified as locally advanced-stage biological behavior[7,8]. Moreover, time to recurrence after curative surgical resection is a critical prognostic factor for clinical outcomes, as early tumor recurrence is associated with worse overall survival (OS). Therefore, postoperative adjuvant treatments may be partly beneficial to decrease the tumor recurrence rates in HCC patients with MVI. Unfortunately, there is still no consensus on the optimal adjuvant treatment after LR or LT for HCC with MVI.

Advances in systemic therapy for advanced HCC, as well as promising strategies for perioperative management of LR, have led to a substantial improvement of surgical outcomes in recent years. Transcatheter arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), as well as targeted therapies based on tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs), are the current state-of-the-art strategies, which have shown great promise in the treatment of advanced HCC[8-12]. However, whether TACE/HAIC, TKIs (such as sorafenib and lenvatinib), and ICIs [such as programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors] are beneficial for decreasing tumor recurrence rates in HCC patients with MVI remains controversial. In view of this, results derived from all the studies were analyzed, aiming to outline the optimal treatment strategy for HCC with MVI after LR. For patients with early-stage HCC, LR, LT, and local ablation (LA) are considered as first-line treatments. However, MVI cannot be precisely evaluated in HCC patients who underwent LA. Therefore, we mainly discuss the effect of postoperative treatments on the surgical outcomes after LT and LR. This review article aims to provide updated information on the recent developments in postoperative adjuvant therapy in HCC patients with MVI.

**LR**

MVI has been widely identified as a crucial risk factor for intrahepatic recurrence after R0 surgical resection, which was evidenced by increased local recurrence rates and reduced recurrence-free survival (RFS) after LR compared to HCC patients without MVI. Whether postoperative adjuvant therapy could improve the surgical outcomes for HCC with MVI remains unclear. There is an urgent need to discuss several postoperative adjuvant treatments such as TACE/HAIC and TKI and ICI therapy, aiming to shed a new light on ways to improve the prognosis for such HCC patients.

***TACE***

The main purpose of TACE after LR is to eliminate the tumor cells released due to compression during operation and destroy the existing microscopic foci in the remnant liver that cannot be found by preoperative imaging examination. It delivers specific drugs, along with iodized oil, mainly to suspected tumor areas, followed by embolization to cause tumor cell necrosis and prevent residual lesions from growing into clinically visible tumors. Some studies demonstrated a superior effect of postoperative TACE in terms of OS and RFS[13,14], while other studies reported comparable results with or without postoperative TACE[15,16]. The benefits of adjuvant TACE in HCC patients with MVI remain controversial. A meta-analysis indicted that adjuvant TACE plus LR may improve the surgical outcomes of HCC patients with MVI compared to LR alone and should be recommended for HCC patients with MVI[17]. Another meta-analysis showed that postoperative adjuvant HAIC could improve the long-term prognosis of HCC patients, especially those with microvascular or macrovascular invasion[18]. A retrospective study showed that postoperative HAIC offers better OS than simple surgical resection in patients with MVI[19]. The beneficial effect of postoperative adjuvant TACE may be related to a number of factors. First, the poor efficacy of surgical resection in patients with liver cancer complicated with MVI is due to the micrometastasis of residual cancer cells before or during LR[20,21]. Postoperative adjuvant TACE can kill or ablate these cells and improve the prognosis. Second, patients with MVI are prone to micrometastasis before surgery[22,23]. Therefore, TACE is a suitable and effective treatment 3-4 wk after LR, when the patients recover from surgery and the residual tumor is still small. Third, the majority of HCC blood supply comes from the hepatic artery, and recurrent tumors often occur near the edge of LR[24,25]. The use of postoperative adjuvant TACE increases the concentration of these marginal local anticancer drugs, which may improve the prognosis of such patients. However, there is no uniform standard for drug combination, dose, frequency of TACE, and time interval of each treatment. Nevertheless, other studies showed conflicting results. A meta-analysis of randomized clinical trials (RCTs) found that TACE did not improve RFS and OS after radical resection of HCC unless the tumor size was 5 cm[26]. A retrospective study showed that adjuvant HAIC using 5-fluorouracil and cisplatin did not improve disease-free survival (DFS) and OS after LR[27]. It remains unclear if HCC patients with MVI can benefit from adjuvant TACE treatment after surgery. The effectiveness of TACE may be due to the fact that chemotherapy drugs enter the blood vessels, and thereby come in contact with the migrating tumor cells to destroy them. However, due to the different tumor microenvironment and tumor heterogeneity in different populations, some patients still cannot benefit from this treatment. The tumor microenvironment may play a key role in the initiation and maintenance of drug resistance through various mechanisms such as pH changes, hypoxia, vascular system abnormalities, changes in immune populations, and extracellular matrix[28].

The pro-tumor environment that induces immunosuppression, such as myeloid-derived suppressor cells, regulatory T cells, and tumor-associated macrophages in the liver immune cell population, may play a major role in the limited effectiveness of chemotherapy drugs. Moreover, chemotherapy drugs themselves may change the composition of the inflammatory cell population[29]. In addition to the interaction of immune cells, hepatocirrhosis microenvironment composes a physical barrier that stimulates tumor growth by altering biomechanical properties, cytokine secretion, and activation of multiple signaling pathways, preventing drugs from reaching targets in the tumor parenchyma and thus reducing drug availability.

Moreover, high-dose TACE can damage liver cells, leading to the deterioration of liver function, reduced immunity against tumor cells, and increased risk of hepatitis B virus reactivation. In TACE, the combined use of multiple drugs may increase the burden on the liver leading to drug-induced liver injury, and ultimately adversely affect the therapeutic effect. Therefore, factors such as liver function and operation time should be considered in postoperative combined TACE treatment[19]. In addition, tumor load, tumor invasion, and postoperative recovery may be factors affecting the efficacy. The relevant studies on the postoperative application of TACE or HAIC as adjuvant therapy are listed in Table 1. However, these results need to be further verified by high-quality RCTs.

***Target therapy-TKIs***

Intrahepatic tumor recurrence after LR can be divided into early recurrence and late recurrence. Early recurrence is related to intrahepatic metastasis of primary tumors that cannot be detected clinically, which may be related to the spread and metastasis of tumor cells in portal vein circulation caused by the shedding of cancer cells before surgery or the pressure exerted on tumors during LR. As liver cancer cells gradually infiltrate the tumor capsule surrounding matrix, and vascular wall, they further invade blood vessels to form MVI. The multi-kinase inhibitors that target tumor cells and tumor blood vessels act on a variety of kinases and pro-angiogenic receptors, blocking downstream signaling pathways, inhibiting the proliferation and promoting apoptosis of tumor cells, as well as inhibiting tumor cell angiogenesis, and migration, with a wide range of anti-tumor effects that promote the prevention and treatment of tumor recurrence[30].

Sorafenib is a multi-kinase inhibitor that blocks multiple molecular pathways through its anti-angiogenic and anti-proliferative effects. A RCT revealed that sorafenib could effectively improve the survival time with advanced HCC patients[31]. In addition, sorafenib has been reported to inhibit postoperative intrahepatic recurrence and abdominal metastasis, thereby extending postoperative survival time[32,33].

Sorafenib can improve the prognosis of MVI in HCC patients after R0 LR. A meta-analysis investigated the preventive effect of sorafenib against tumor recurrence in HCC with MVI, and the results showed that LR plus sorafenib significantly improves the prognosis of HCC with MVI compared to LR alone. However, this meta-analysis has some shortcomings. First, it only included retrospective studies, which may cause selection bias. Second, the patients in these four studies were all Chinese, which also weakens the universality of the conclusion[34].

Recent studies have demonstratedthe efficacy of sorafenib in preventing recurrence of HCC after LR[35]. Li *et al*[36] as well as Xia *et al*[37] found that the OS and DFS of Barcelona Clinic Liver Cancer stage C HCC patients treated with oral sorafenib after LR was significantly longer than those of patients only treated by LR. Wang *et al*[38] proved that sorafenib as an adjuvant therapy for HCC can prevent early recurrence after LR. Huang *et al*[39] evaluated the impact of sorafenib as an adjuvant therapy on the clinical outcomes in HCC with MVI. The results indicated that adjuvant sorafenib significantly prolonged both OS and RFS of patients with HCC after radical resection.

However, a RCT revealed that sorafenib treatment after LR did not improve the DFS of HCC patients, but increased the incidence of side effects, such as hand-foot skin reaction, diarrhea, and fatigue[40]. Similarly, it was found that postoperative sorafenib adjuvant therapy cannot improve RFS in HCC patients with MVI[41]. The relevant studies on postoperative application of TKIs as adjuvant therapy are listed in Table 2. There are differences in the results from different centers. In addition to the sample size and research methods that may affect the results, these differences may also be caused by different definitions and classifications of MVI. It may be necessary to conduct systematic research under uniform definitions and standards to make the results more comparable.

Although targeted drugs have greatly improved the prognosis of patients with advanced liver cancer, the efficacy of single drugs is still limited, and drug resistance may occur during treatment due to tumor heterogeneity and changes in the immune microenvironment. In addition, the side effects of drugs and the tolerance of patients also affect the therapeutic effect. In the future, it may be necessary to standardize the population suitable for targeted therapy, and consider combined therapy to improve the efficacy when single drugs are insufficient. In view of the above results, the role of targeted drugs as adjuvant therapy may still be controversial, and a large number of prospective RCTs are needed to further verify their efficacy in the future.

***PD-1/PD-L1 treatment***

ICIs are a new class of anti-tumor drugs that target regulatory signals between T cells, target cells, and other immune cells. T cells can recognize specific antigens presented on target cells by major histocompatibility complex proteins through their T cell receptors, and can induce apoptosis of target cells. T-cell activity is precisely regulated by co-stimulatory and co-inhibitory molecules to maintain an appropriate immune response without harmful overactivation. Therefore, adjuvant application of ICI after LR, may activate T cells to destroy circulating tumor cells and prevent recurrence.

At present, the main immune checkpoint molecules targeted by immunotherapy are PD-1, PD-L1, and cytotoxic T lymphocyte-associated protein 4. Cancer immunotherapy may have a significant impact in adjuvant settings, as it can immediately induce tumor cell killing and potentially produce durable immune responses that eliminate residual micrometastases that are thought to lead to early recurrence. Anti-PD-1/PD-L1 antibody, either alone or in combination, has shown successful induction of pathological reactions in a variety of tumor types, while also inducing tumor-specific T cell amplification, which may produce a vaccine effect capable of systemic monitoring[42,43]. The response rate to PD-1 blockade is about 20%, and the response to combined therapy may be higher[44,45].

At present, no large-scale clinical datasets have confirmed the role of ICIs in preventing postoperative recurrence and improving long-term survival in HCC. CheckMate-9DX is an ongoing trial investigating whether nivolumab can improve RFS compared with placebo in HCC patients who have a high risk of recurrence after LR or ablation, which includes patients with MVI.

Prevention of postoperative recurrence is an important part of the treatment of HCC, which is still an unsolved clinical problem. For early operable HCC with MVI, optimal liver function reserve, good physical condition, and increased tolerance to immune-related toxicity may improve the curative opportunity of the patients. However, the response of such patients to immunotherapy or drug resistance is still a challenge that cannot be ignored.

Considering the potential adverse reactions to combined administration, it is particularly important to select specific patients that most likely benefit from such therapies. Therefore, it is necessary to establish an effective predictive model, and a large number of prospective clinical studies are still needed to provide reliable guidance. In addition, there are studies on targeted drugs combined with immunotherapy for postoperative assistance, as shown in Table 3. We expect these effective research results to provide a reference for clinical decision-making. Since MVI is one of the critically important risk factors for relapse and metastasis, surgical resection alone may not completely eliminate the adverse effects of MVI and improve the prognosis of patients. Although there is no uniform standard for adjuvant therapy after LR, it may be one of the most promising strategies to improve the efficacy HCC therapy in patients with MVI.

**LT**

LT is suitable for patients with early HCC[46], but unfortunately, many patients are diagnosed at an advanced stage. Although many centers have expanded the indications beyond the Milan criteria and achieved promising results, there is still a high risk of relapse after transplantation, with HCC recurrence peaking about 2-3 years after LT[47-50].

Theoretically, LT completely eliminates tumors and potential lesions in the liver. However, MVI or undetected extrahepatic lesions can lead to HCC recurrence after transplantation. MVI was reported to be a major risk factor for HCC recurrence after LT[51]. Milan and other similar criteria are based on tumor size according to imaging, which does not provide sufficient information about pathological features and tumor biology, such as MVI and differentiation/grade. Therefore, these criteria cannot fully predict the recurrence of HCC after LT. MVI in the liver can predict tumor recurrence and indicate a poor prognosis. However, although MVI is an important predictor of tumor recurrence, without pathological examination, it is almost impossible to detect MVI before LT. Therefore, MVI largely determines the long-term prognosis of patients after resection and transplantation[52]. Theoretically, adjuvant therapy after LT may eradicate residual tumor cells in the blood. Therefore, it is very important to explore adjuvant therapy to improve the survival rate after transplantation.

At present, there is no systematic adjuvant therapy for HCC patients with MVI after transplantation, and most of the related studies focused on the treatment of recurrence after transplantation. Only some studies investigated adjuvant treatments for patients with a high risk of recurrence after transplantation beyond the Milan criteria. Nevertheless, patients with MVI were included in these studies, as summarized below and listed in Table 4.

There is a high burden of early immunosuppression, especially in the case of calcineurin inhibitors such as cyclosporine and tacrolimus, which are usually the basic drugs against organ rejection after transplantation and may also increase the risk of HCC recurrence[53-55]. By contrast, immunosuppressive regimens based on mammalian target of rapamycin inhibitors, such as sirolimus and everolimus, have antitumor properties *in vitro* and *in vivo* and may reduce the HCC recurrence rates. Unfortunately, a prospective phase III multicenter RCT showed no significant improvement of the recurrence rate in HCC transplant recipients treated with sirolimus[56].

Some small studies have shown that sorafenib can improve the survival rate of LT patients with a high risk of recurrence after transplantation[33], but there is also evidence against chemotherapy or sorafenib adjuvant therapy after LT[57]. Whether targeted drugs are suitable for LT patients with MVI therefore remains to be verified in the future. Overall, there is no evidence that systemic adjuvant chemotherapy after LT can prevent HCC recurrence[58].

Although ICIs have demonstrated a certain level of efficacy in advanced liver cancer, based on the characteristics of ICIs and the special physical condition of patients after LT, balancing graft-protective immunosuppression and anti-tumor immune enhancement is still an unresolved issue. The use of ICIs as adjuvant therapy in transplant recipients has been the subject of several case reports[58-62], but ICIs may promote allograft injury[63], leading to severe rejection and even death. When systematically evaluating the data of cancer transplant recipients receiving ICIs, 37.5% of the recipients experienced liver allograft rejection, resulting in a 75% incidence of end-stage organ failure[64]. PD-1 inhibitor therapy after LT was reported in eight cases, including two cases of graft rejection[58,60,65]. Even if the treatment strategy of combined ICIs has great prospects, clinicians should be extremely cautious in practical application.

Tumor cell invasion of microscopic blood vessels in the surrounding liver tissue adjacent to the tumor is a histological feature of HCC. In recent years, several studies have intended to classify MVI based on different features[66-68], indicating that MVI can be further classified as MI and microscopic portal vein invasion (MPVI)[69,70], where tumor cells may invade the microvessels at the initial stage of invasion, while the newly formed microvascular structure due to the interaction of liver tissue around the tumor is defined as MI. Subsequently, as tumor invasion accelerates, tumor cells float and settle in the portal vein branches farther away from the original tumor, which is defined as MPVI. Unfortunately, MVI can only be definitively diagnosed by examining surgical specimens, limiting its role in guiding individualized treatment. The two types of MVI have different foundations and mechanisms. MPVI is a more advanced form of tumor invasion than MI. Patients with MPVI have more aggressive tumor characteristics, and the two different risk factors for recurrence suggest that the goals should be different when designing adjuvant therapy for each type. For MI, the main strategy should be targeted at disseminated tumor cells that spread from the primary tumor[7]. For MPVI, a potentially systemic treatment strategy is more appropriate. Our preliminary study indicated that postoperative adjuvant therapy could improve long-term outcomes after curative LR in HCC patients with MPVI, but the effect was weaker in MI. At the same time, our studies have shown that in MI, a wider surgical margin can eliminate peripheral intrahepatic micrometastasis, thereby preventing early tumor recurrence. By contrast, the surgical results of MPVI patients are similar regardless of the width of the surgical margin[71].

Therefore, it may not be wise to classify the two types of vascular invasion into one group for research and analysis, while more appropriate treatment strategies should be developed based on different biological and histological characteristics. Several limitations exist in this study. First, the prognosis of HCC is affected by a variety of factors including tumor markers, tumor size, tumor differentiation, and liver cancer staging, here, we only give a systematic review of the prognosis of patients with MVI, not considering other factors. Second, since adjuvant therapy after LT with MVI is relatively limited, the results obtained may not objectively reflect its efficacy. Third, we did not categorize all studies using meta-analysis, so there may still be valid treatment outcomes missed. Thus, more clinical studies may be needed to analyze the postoperative adjuvant therapy for such populations in order to obtain the best treatment strategy.

**CONCLUSION**

Adjuvant therapy for preventing tumor recurrence after radical resection in HCC patients with MVI is the key to improving the long-term survival rate. Although there is still controversy, after LR, TACE may be an effective choice to improve DFS and OS. As targeted therapy and immunotherapy have been effective in improving the prognosis of patients with advanced liver cancer in many retrospective studies, adjuvant therapy based on molecular targeted drugs needs further study. Many RCT studies evaluating adjuvant ICI after LR are ongoing, and their results may provide additional references for adjuvant therapy. In the future, prospective studies should be carried out to clarify the improvement of prognosis in the MVI subgroup by these two treatments. Moreover, in consideration of the actual drug efficacy, adverse reactions, and patient tolerance, the relationship between efficacy and safety should be balanced in clinical practice. It may be necessary to distinguish potential populations benefiting from each combination therapy, and to assess whether patients have the preconditions to receive effective combination therapy using novel biomarkers and biological characteristics.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 **Maluccio M**, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. *CA Cancer J Clin* 2012; **62**: 394-399 [PMID: 23070690 DOI: 10.3322/caac.21161]

3 **Chen ZH**, Zhang XP, Zhou TF, Wang K, Wang H, Chai ZT, Shi J, Guo WX, Cheng SQ. Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. *Eur J Surg Oncol* 2019; **45**: 2188-2196 [PMID: 31256949 DOI: 10.1016/j.ejso.2019.06.031]

4 **Kluger MD**, Salceda JA, Laurent A, Tayar C, Duvoux C, Decaens T, Luciani A, Van Nhieu JT, Azoulay D, Cherqui D. Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. *J Hepatol* 2015; **62**: 1131-1140 [PMID: 25529622 DOI: 10.1016/j.jhep.2014.12.018]

5 **Zhang EL**, Cheng Q, Huang ZY, Dong W. Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion. *Front Oncol* 2021; **11**: 691354 [PMID: 34123861 DOI: 10.3389/fonc.2021.691354]

6 **Zhang XP**, Wang K, Wei XB, Li LQ, Sun HC, Wen TF, Chai ZT, Chen ZH, Shi J, Guo WX, Xie D, Cong WM, Wu MC, Lau WY, Cheng SQ. An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. *Oncologist* 2019; **24**: e1476-e1488 [PMID: 31138726 DOI: 10.1634/theoncologist.2018-0868]

7 **Wang H**, Feng LH, Qian YW, Cao ZY, Wu MC, Cong WM. Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior? *Ann Transl Med* 2019; **7**: 428 [PMID: 31700864 DOI: 10.21037/atm.2019.08.114]

8 **Leone P**, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. *Vaccines (Basel)* 2021; **9** [PMID: 34065489 DOI: 10.3390/vaccines9050532]

9 **Liu ZL**, Liu JH, Staiculescu D, Chen J. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. *Ther Adv Med Oncol* 2021; **13**: 17588359211018026 [PMID: 34104226 DOI: 10.1177/17588359211018026]

10 **Granito A**, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. *Therap Adv Gastroenterol* 2021; **14**: 17562848211016959 [PMID: 34104211 DOI: 10.1177/17562848211016959]

11 **Patsoukis N**, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. *Sci Adv* 2020; **6** [PMID: 32948597 DOI: 10.1126/sciadv.abd2712]

12 **Li QJ**, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. *J Clin Oncol* 2022; **40**: 150-160 [PMID: 34648352 DOI: 10.1200/JCO.21.00608]

13 **Ye JZ**, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. *World J Gastroenterol* 2017; **23**: 7415-7424 [PMID: 29151695 DOI: 10.3748/wjg.v23.i41.7415]

14 **Chen W**, Ma T, Zhang J, Zhang X, Chen W, Shen Y, Bai X, Liang T. A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. *HPB (Oxford)* 2020; **22**: 795-808 [PMID: 31980307 DOI: 10.1016/j.hpb.2019.12.013]

15 **Chen XH**, Zhang BH, Qiu SJ, Fan J, Ren ZG, Xia JL, Wang YH, Gan YH, Yin X, Ye SL. [Effect of postoperative adjuvant transarterial chemoembolization on late recurrence of hepatocellular carcinoma after radical resection]. *Zhonghua Gan Zang Bing Za Zhi* 2010; **18**: 599-603 [PMID: 20825715 DOI: 10.3760/cma.j.issn.1007-3418.2010.08.012]

16 **Yang Y**, Lin K, Liu L, Qian Y, Yang Y, Yuan S, Zhu P, Huang J, Liu F, Gu F, Fu S, Jiang B, Liu H, Pan Z, Lau WY, Zhou W. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis. *Cancer Med* 2021; **10**: 2100-2111 [PMID: 33650288 DOI: 10.1002/cam4.3814]

17 **Li S**, Mei J, Wang Q, Guo Z, Lu L, Ling Y, Xu L, Chen M, Zheng L, Lin W, Zou J, Wen Y, Wei W, Guo R. Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial. *Ann Surg Oncol* 2020; **27**: 5183-5190 [PMID: 32418078 DOI: 10.1245/s10434-020-08601-8]

18 **Ke Q**, Wang L, Wu W, Huang X, Li L, Liu J, Guo W. Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma. *Front Oncol* 2021; **11**: 720079 [PMID: 35004268 DOI: 10.3389/fonc.2021.720079]

19 **Hsiao JH**, Tsai CC, Liang TJ, Chiang CL, Liang HL, Chen IS, Chen YC, Chang PM, Chou NH, Wang BW. Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment. *Int J Surg* 2017; **45**: 35-41 [PMID: 28728985 DOI: 10.1016/j.ijsu.2017.07.071]

20 **Shah SA**, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. *Surgery* 2007; **141**: 330-339 [PMID: 17349844 DOI: 10.1016/j.surg.2006.06.028]

21 **Yamanaka N**, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, Fujimoto J, Oriyama T, Furukawa K, Kawamura E. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. *Cancer* 1990; **65**: 1104-1110 [PMID: 2154320 DOI: 10.1002/1097-0142(19900301)65:5<1104::aid-cncr2820650511>3.0.co;2-g]

22 **Bruix J**, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

23 **Tsai TJ**, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Hsia CY, Wu CW. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. *Surgery* 2000; **127**: 603-608 [PMID: 10840353 DOI: 10.1067/msy.2000.105498]

24 **Yoshida Y**, Kanematsu T, Matsumata T, Takenaka K, Sugimachi K. Surgical margin and recurrence after resection of hepatocellular carcinoma in patients with cirrhosis. Further evaluation of limited hepatic resection. *Ann Surg* 1989; **209**: 297-301 [PMID: 2538106 DOI: 10.1097/00000658-198903000-00008]

25 **Matsumata T**, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. *Hepatology* 1989; **9**: 457-460 [PMID: 2537789 DOI: 10.1002/hep.1840090320]

26 **Cheng X**, Sun P, Hu QG, Song ZF, Xiong J, Zheng QC. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. *J Cancer Res Clin Oncol* 2014; **140**: 1159-1170 [PMID: 24752339 DOI: 10.1007/s00432-014-1677-4]

27 **Kim DY**, Ahn SH, Kim SU, Choi SB, Lee KH, Park MS, Park JY, Lee DY, Han KH, Kim KS. Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. *Oncology* 2011; **81**: 184-191 [PMID: 22067673 DOI: 10.1159/000333827]

28 **Wang L**, Ke Q, Lin N, Zeng Y, Liu J. Does postoperative adjuvant transarterial chemoembolization benefit for all patients with hepatocellular carcinoma combined with microvascular invasion: a meta-analysis. *Scand J Gastroenterol* 2019; **54**: 528-537 [PMID: 31081401 DOI: 10.1080/00365521.2019.1610794]

29 **Xiao EH**, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. *World J Gastroenterol* 2009; **15**: 4582-4586 [PMID: 19777619 DOI: 10.3748/wjg.15.4582]

30 **Isik B**, Gonultas F, Sahin T, Yilmaz S. Microvascular Venous Invasion in Hepatocellular Carcinoma: Why Do Recurrences Occur? *J Gastrointest Cancer* 2020; **51**: 1133-1136 [PMID: 32839943 DOI: 10.1007/s12029-020-00487-9]

31 **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]

32 **Feng YX**, Wang T, Deng YZ, Yang P, Li JJ, Guan DX, Yao F, Zhu YQ, Qin Y, Wang H, Li N, Wu MC, Wang HY, Wang XF, Cheng SQ, Xie D. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. *Hepatology* 2011; **53**: 483-492 [PMID: 21274870 DOI: 10.1002/hep.24075]

33 **Saab S**, McTigue M, Finn RS, Busuttil RW. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. *Exp Clin Transplant* 2010; **8**: 307-313 [PMID: 21143097]

34 **Gu W**, Tong Z. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. *J Int Med Res* 2020; **48**: 300060520946872 [PMID: 32815430 DOI: 10.1177/0300060520946872]

35 **Li Z**, Han N, Ren X, Zhang Y, Chu X. Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study. *Front Oncol* 2022; **12**: 833884 [PMID: 35433466 DOI: 10.3389/fonc.2022.833884]

36 **Li J**, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. *World J Gastroenterol* 2016; **22**: 4034-4040 [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034]

37 **Xia F**, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. *World J Gastroenterol* 2016; **22**: 5384-5392 [PMID: 27340354 DOI: 10.3748/wjg.v22.i23.5384]

38 **Wang SN**, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. *Hepatol Res* 2014; **44**: 523-531 [PMID: 23672310 DOI: 10.1111/hepr.12159]

39 **Huang Y**, Zhang Z, Zhou Y, Yang J, Hu K, Wang Z. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? *Onco Targets Ther* 2019; **12**: 541-548 [PMID: 30666133 DOI: 10.2147/OTT.S187357]

40 **Bruix J**, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2015; **16**: 1344-1354 [PMID: 26361969 DOI: 10.1016/S1470-2045(15)00198-9]

41 **Li Q**, Song T. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. *Front Oncol* 2021; **11**: 633033 [PMID: 34631511 DOI: 10.3389/fonc.2021.633033]

42 **Topalian SL**, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. *Science* 2020; **367** [PMID: 32001626 DOI: 10.1126/science.aax0182]

43 **Huang AC**, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nat Med* 2019; **25**: 454-461 [PMID: 30804515 DOI: 10.1038/s41591-019-0357-y]

44 **El-Khoueiry AB**, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; **389**: 2492-2502 [PMID: 28434648 DOI: 10.1016/S0140-6736(17)31046-2]

45 **Finn RS**, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med* 2020; **382**: 1894-1905 [PMID: 32402160 DOI: 10.1056/NEJMoa1915745]

46 **Clavien PA**, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. *Lancet Oncol* 2012; **13**: e11-e22 [PMID: 22047762 DOI: 10.1016/S1470-2045(11)70175-9]

47 **Sapisochin G**, Goldaracena N, Astete S, Laurence JM, Davidson D, Rafael E, Castells L, Sandroussi C, Bilbao I, Dopazo C, Grant DR, Lázaro JL, Caralt M, Ghanekar A, McGilvray ID, Lilly L, Cattral MS, Selzner M, Charco R, Greig PD. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series. *Ann Surg Oncol* 2015; **22**: 2286-2294 [PMID: 25472651 DOI: 10.1245/s10434-014-4273-6]

48 **Sharma P**, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. *Dig Dis Sci* 2012; **57**: 806-812 [PMID: 21953139 DOI: 10.1007/s10620-011-1910-9]

49 **Roayaie S**, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. *Liver Transpl* 2004; **10**: 534-540 [PMID: 15048797 DOI: 10.1002/Lt.20128]

50 **Fernandez-Sevilla E**, Allard MA, Selten J, Golse N, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Adam R. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? *Liver Transpl* 2017; **23**: 440-447 [PMID: 28187493 DOI: 10.1002/lt.24742]

51 **Agopian VG**, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. *J Am Coll Surg* 2015; **220**: 416-427 [PMID: 25690672 DOI: 10.1016/j.jamcollsurg.2014.12.025]

52 **Hou YF**, Li B, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LV, Chen KF. Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria. *Medicine (Baltimore)* 2015; **94**: e2070 [PMID: 26632890 DOI: 10.1097/MD.0000000000002070]

53 **Rodríguez-Perálvarez M**, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. *J Hepatol* 2013; **59**: 1193-1199 [PMID: 23867318 DOI: 10.1016/j.jhep.2013.07.012]

54 **Vivarelli M**, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. *Liver Transpl* 2005; **11**: 497-503 [PMID: 15838913 DOI: 10.1002/Lt.20391]

55 **Vivarelli M**, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. *Ann Surg* 2008; **248**: 857-862 [PMID: 18948815 DOI: 10.1097/SLA.0b013e3181896278]

56 **Geissler EK**, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. *Transplantation* 2016; **100**: 116-125 [PMID: 26555945 DOI: 10.1097/TP.0000000000000965]

57 **Pelizzaro F**, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. *Cancers (Basel)* 2021; **13** [PMID: 34638365 DOI: 10.3390/cancers13194882]

58 **Dunn GP**, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol* 2002; **3**: 991-998 [PMID: 12407406 DOI: 10.1038/ni1102-991]

59 **Lipson EJ**, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. *J Clin Oncol* 2014; **32**: e69-e71 [PMID: 24493726 DOI: 10.1200/JCO.2013.49.2314]

60 **Biondani P**, De Martin E, Samuel D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient. *Ann Oncol* 2018; **29**: 286-287 [PMID: 29293878 DOI: 10.1093/annonc/mdx548]

61 **DeLeon TT**, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, Moss AA, Mathur AK, Chascsa DM, Rakela J, Bryce AH, Borad MJ. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. *J Gastrointest Oncol* 2018; **9**: 1054-1062 [PMID: 30603124 DOI: 10.21037/jgo.2018.07.05]

62 **Lipson EJ**, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. *N Engl J Med* 2016; **374**: 896-898 [PMID: 26962927 DOI: 10.1056/NEJMc1509268]

63 **Gassmann D**, Weiler S, Mertens JC, Reiner CS, Vrugt B, Nägeli M, Mangana J, Müllhaupt B, Jenni F, Misselwitz B. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research. *Transplant Direct* 2018; **4**: e376 [PMID: 30255136 DOI: 10.1097/TXD.0000000000000814]

64 **d'Izarny-Gargas T**, Durrbach A, Zaidan M. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review. *Am J Transplant* 2020; **20**: 2457-2465 [PMID: 32027461 DOI: 10.1111/ajt.15811]

65 **Varkaris A**, Lewis DW, Nugent FW. Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma. *Am J Gastroenterol* 2017; **112**: 1895-1896 [PMID: 29215617 DOI: 10.1038/ajg.2017.387]

66 **Roayaie S**, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. *Gastroenterology* 2009; **137**: 850-855 [PMID: 19524573 DOI: 10.1053/j.gastro.2009.06.003]

67 **Iguchi T**, Shirabe K, Aishima S, Wang H, Fujita N, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T, Oda Y, Maehara Y. New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation. *Transplantation* 2015; **99**: 1236-1242 [PMID: 25427164 DOI: 10.1097/TP.0000000000000489]

68 **Feng LH**, Dong H, Lau WY, Yu H, Zhu YY, Zhao Y, Lin YX, Chen J, Wu MC, Cong WM. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2017; **143**: 293-303 [PMID: 27743138 DOI: 10.1007/s00432-016-2286-1]

69 **Zhao H**, Chen C, Fu X, Yan X, Jia W, Mao L, Jin H, Qiu Y. Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocellular carcinoma after resection. *Oncotarget* 2017; **8**: 5474-5486 [PMID: 27729623 DOI: 10.18632/oncotarget.12547]

70 **Fujita N**, Aishima S, Iguchi T, Mano Y, Taketomi A, Shirabe K, Honda H, Tsuneyoshi M, Oda Y. Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. *Hum Pathol* 2011; **42**: 1531-1538 [PMID: 21496875 DOI: 10.1016/j.humpath.2010.12.016]

71 **Zhang EL**, Chen XP, Huang ZY. Comment on "Sub-classification of Microscopic Vascular Invasion in Hepatocellular Carcinoma". *Ann Surg* 2021; **274**: e926-e927 [PMID: 34225290 DOI: 10.1097/SLA.0000000000005036]

72 **Sun JJ**, Wang K, Zhang CZ, Guo WX, Shi J, Cong WM, Wu MC, Lau WY, Cheng SQ. Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion. *Ann Surg Oncol* 2016; **23**: 1344-1351 [PMID: 26714945 DOI: 10.1245/s10434-015-5008-z]

73 **Wei W**, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, Lin XJ, Xu L, Shi M, Zheng L, Chen MS, Guo RP. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. *Cancer Commun (Lond)* 2018; **38**: 61 [PMID: 30305149 DOI: 10.1186/s40880-018-0331-y]

74 **Liu C**, Sun L, Xu J, Zhao Y. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. *World J Surg Oncol* 2016; **14**: 100 [PMID: 27038790 DOI: 10.1186/s12957-016-0855-z]

75 **Wang YY**, Wang LJ, Xu D, Liu M, Wang HW, Wang K, Zhu X, Xing BC. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion. *HPB (Oxford)* 2019; **21**: 425-433 [PMID: 30249510 DOI: 10.1016/j.hpb.2018.08.001]

76 **Cai J**, Zhao J, Liu D, Xie H, Qi H, Ma J, Sun Z, Zhao H. Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study. *Front Oncol* 2021; **11**: 781029 [PMID: 34926296 DOI: 10.3389/fonc.2021.781029]

77 **Nitta H**, Beppu T, Imai K, Hayashi H, Chikamoto A, Baba H. Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. *World J Surg* 2013; **37**: 1034-1042 [PMID: 23435678 DOI: 10.1007/s00268-013-1957-1]

78 **Friend BD**, Venick RS, McDiarmid SV, Zhou X, Naini B, Wang H, Farmer DG, Busuttil RW, Federman N. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. *Pediatr Blood Cancer* 2017; **64** [PMID: 28643391 DOI: 10.1002/pbc.26682]

79 **Iavarone M**, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. *Am J Transplant* 2019; **19**: 3176-3184 [PMID: 31365177 DOI: 10.1111/ajt.15551]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** September 21, 2022

**First decision:** October 18, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Nath L, India; Ullah K, Pakistan **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:**

**Table 1 Transcatheter arterial chemoembolization approved as an adjuvant therapy for hepatocellular carcinoma patients with microvascular invasion**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study type** | **Adjuvant therapy** | **Number** | **2-yr DFS (%)** | ***P* value** | **2-yr OS (%)** | ***P* value** | **PMID** |
| Li *et al*[17] | RCT | HAIC | 63 | 58.7 | 0.023 | 97.7 | 0.037 | 32418078 |
| NAT | 64 | 38.6 |  | 78.5 |  |
| Sun *et al*[72] | Retrospective | TACE | 137 | 55.5 | 0.012 | 78.8 | 0.006 | 26714945 |
| NAT | 185 | 36.2 |  | 62.2 |  |
| Wei *et al*[73] | RCT | TACE | 125 | 44.7 | 0.02 | 64.3 | 0.029 | 30305149 |
| NAT | 125 | 30.6 |  | 49.8 |  |
| Ye *et al*[13] | Retrospective | TACE | 86 | 58.3 | 0.002 | 86.5 | 0.019 | 29151695 |
| NAT | 174 | 41.1 |  | 65.7 |  |
| Liu *et al*[74] | Retrospective | TACE | 24 | 26.9 | 0.03 | NA | NA | 27038790 |
| NAT | 26 | 4.2 |  | NA |  |
| Wang *et al*[75] | Retrospective | TACE | 57 | 66 | 0.008 | 94 | 0.04 | 30249510 |
| NAT | 57 | 50 |  | 83 |  |
| Cai *et al*[76] | Retrospective | TACE | 25 | 39.1 | 0.06 | NA | NA | 34926296 |
| TACE + T cell self | 23 | 58.2 |  | NA |  |
| Kim *et al*[27] | RCT | HAIC | 31 | 9.1 | 0.324 | 87.1 | 0.561 | 22067673 |
| NAT | 62 | 4.2 |  | 78.3 |  |
| *Nitta* et al[77] | Retrospective | HAIC | 38 | 33.1 |  | 56.2 | 0.318 | 23435678 |

DFS: Disease-free survival; OS: Overall survival; TACE: Transcatheter arterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; NAT: No adjuvant therapy; NA: Not available; RCT: Randomized clinical trial.

**Table 2 Tyrosine kinase inhibitor approved as an adjuvant therapy for hepatocellular carcinoma patients with microvascular invasion**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **NCT number** | **Title** | **Interventions** | **Characteristics** | ***n*** | **Date** | **Current status** |
| NCT02678806 | Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (< 1 cm) and/or Microvascular Invasion (RHCC:BCLC-A) | Radiation: Postoperative radiotherapy. Drug: Postoperative TACE | Phase: Not applicable. Allocation: Randomized. Intervention model: Parallel. Outcome measures: Overall survival | 620 | November 1, 2017 to November 1, 2022 | Recruiting |
| NCT04053972 | The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy: A Random, Controlled, Stage III Clinical Trial | Drug: Lenvatinib | Phase: 3. Allocation: Randomized. Intervention model: Parallel. Outcome measures: RFS and OS recurrence rate | 377 | January 31, 2018 to December 31, 2022 | Recruiting |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection | Drug: Sorafenib | Phase: 3. Allocation: Non\_x005f randomized. Outcome measures: Recurrence free survival; time to recurrence; recurrence rate; overall survival; incidence of treatment related; adverse events; incidence of dose modification of sorafenib due to adverse events | 154 | June 1, 2016 to January 31, 2020 | Terminated |
| NCT03192618 | The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy: A Random, Controlled, Stage III Clinical Trial | Procedure: Adjuvant transarterial chemoinfusion. Drug: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-fluorouracil) | Phase: 3. Allocation: Randomized. Outcome measures: DFS; recurrence rate; OS | 290 | July 1, 2017 to December 31, 2024 | Recruiting |
| NCT02436902 | Adjuvant Therapies for Patients With HCC and MVI | Procedure: TACE. Drug: Sorafenib, TACE plus sorafenib and empty control | Phase: 3. Allocation: Non\_x005f randomized. Outcome measures: Overall survivals; hospital mortality; recurrence rates | 240 | February 1, 2019 to August 30, 2022 | Recruiting |
| NCT03732105 | Radiotherapy/Apatinib for Adjuvant Treatment of HCC Patients receIved Curative resection With Microvascular Invasion | Radiotherapy. Drug: Apatinib and radiotherapy + apatinib | Phase: 2. Allocation: Randomized. Outcome measures: RFS; time to recurrence; overall survival; safety events; health related quality of life | 160 | November 1, 2018 to December 31, 2023 | Not yetrecruiting |
| NCT03575806 | Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection | Combination product: TACE plus autologous Tcm immunotherapy. Procedure: TACE | Phase: 2. Allocation: Non\_x005f randomized. Outcome measures: RFS time; OS rate at 24 mo | 52 | January 9, 2017 to October 31, 2019 | Completed |
| Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? | Drug: Sorafenib | Phase: Not applicable. Allocation: Retrospective study. Outcome measures: DFS; recurrence rate; OS | 49 | January, 2009 to December, 2016 | Completed |
| Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma | Procedure: TACE. Drug: Sorafenib, TACE plus sorafenib, and TACE | Phase: Not applicable. Allocation: Retrospective study. Outcome measures: DFS; recurrence rate; OS | 127 | January, 2010 to December, 2016 | Completed |
| Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis | Drug: Sorafenib | Phase: Not applicable. Allocation: Retrospective study. Outcome measures: DFS; recurrence rate; OS | 728 | January, 2009 to December, 2016 | Completed |
| NCT00692770 | Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial | Drug: Sorafenib | Phase: 3. Allocation: Randomized. Outcome measures: DFS; recurrence rate; OS | 1114 | August 15, 2008 to November 17, 2010 | Completed |

TACE: Transcatheter arterial chemoembolization; DFS: Disease-free survival; OS: Overall survival; RFS: Recurrence-free survival; HCC: Hepatocellular carcinoma; MVI: Microvascular invasion.

**Table 3 Immune checkpoint inhibitors as an adjuvant therapy for hepatocellular carcinoma patients with microvascular invasion**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **NCT number** | **Title** | **Interventions** | **Characteristics** | ***n*** | **Date** | **Current status** |
| NCT04682210 | Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection | Drug: Sintilimab. Drug: Bevacizumab | Phase: 3. Allocation: Randomized. Intervention model: Parallel | 246 | December, 2020 to December, 2024 | Not yet recruiting |
| NCT04981665 | A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | Drug: Tislelizumab. Drug: TACE | Phase: 2. Allocation: N/A. Intervention model: Single group assignment | 50 | November 8, 2021 to December, 2024 | Recruiting |
| NCT05407519 | A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | Drug: Tislelizumab. Drug: Sitravatinib | Phase: 2. Allocation: N/A. Intervention model: Single group assignment | 52 | July 25, 2022 to June 30, 2026 | Recruiting |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | Drug: Camrelizumab.Drug: Rivoceranib (apatinib) | Phase: 3. Allocation: Randomized. Intervention model: Crossover assignment | 674 | April 1, 2021 to July 31, 2024 | Recruiting |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | Drug: Apatinib Mesylate. Drug: SHR-1210 | Phase: 2. Allocation: Randomized. Intervention model: Parallel | 200 | February 15, 2019 to February 28, 2023 | Not yet recruiting |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) | Drug: Durvalumab. Drug: Bevacizumab. Other: Placebo | Phase: 3. Allocation: Randomized. Intervention model: Parallel | 908 | April 29, 2019 to May 31, 2024 | Not yet recruiting |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050) | Drug: Atezolizumab. Drug: Bevacizumab | Phase: 3. Allocation: Randomized. Intervention model: Parallel | 668 | December 31, 2019 to July 16, 2027 | Not yet recruiting |

TACE: Transcatheter arterial chemoembolization; HCC: Hepatocellular carcinoma.

**Table 4 Adjuvant therapy after liver transplantation**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Interventions** | **Characteristics** | ***n*** | **Result** | **PMID** |
| Rodríguez-Perálvarez *et al*[53] | Drug: mTOR inhibitors | Multicenter retrospective study | 219 | Effective | 23867318 |
| Vivarelli *et al*[54] | Drug: Cyclosporine | Retrospective study | 70 | Effective | 15838913 |
| Vivarelli *et al*[55] | Drug: Tacrolimus | Retrospective study | 139 | Ineffective | 18948815 |
| Geissler *et al*[56] | Drug: Sirolimus | Phase: 3. Allocation: Randomized. Intervention model: Parallel | 525 | Ineffective | 26555945 |
| Friend *et al*[78]  | Drug: Nivolumab | Retrospective study | 2 | Ineffective | 28643391 |
| Biondani *et al*[60] | Drug: Nivolumab | Case report | 1 | Ineffective | 29293878 |
| DeLeon *et al*[61] | Drug: PD-1/PD-L1 inhibitors | Retrospective study | 7 | Partly effective | 30603124 |
| Gassmann *et al*[63]  | Drug: Nivolumab | Case report | 1 | Ineffective | 30255136 |
| Varkaris *et al*[65] | Drug: Pembrolizumab | Case report | 1 | Ineffective | 29215617 |
| Iavarone *et al*[79] | Drug: Sorafenib | Multicenter retrospective study | 28 | Ineffective | 31365177 |

mTOR: Mammalian target of rapamycin; PD-1: Programmed cell death protein 1; PD-L1: Programmed death ligand 1.